Greenwich LifeSciences GLSI
NASDAQ GLSI
$15.84 +0.21 (+1.34%)
As of: Sep 4, 2026 · 3:55 PM EDT

Greenwich LifeSciences (GLSI) Total Non-Current Liabilities (2024 - 2026)

Greenwich LifeSciences' (GLSI) quarterly Total Non-Current Liabilities came in at $5.2 million in Q4 2025, up 78.92% YoY from $2.9 million in Q4 2024, and up 132.6% on a QoQ basis from $2.2 million in Q2 2025.

Analysis

Greenwich LifeSciences (GLSI) Total Non-Current Liabilities (2024 - 2026) Analysis & Trends

Greenwich LifeSciences (GLSI) has 2 years of Total Non-Current Liabilities data on file, last reported at $5.2 million in Q4 2025.

  • Quarterly Total Non-Current Liabilities rose 78.92% year-over-year to $5.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.2 million (up 78.92% YoY) and the FY2025 annual result came in at $5.2 million, up 78.92% from the prior year.
  • Total Non-Current Liabilities rose to $5.2 million in Q4 2025, from $2.2 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $5.2 million in Q4 2025 to a low of $2.2 million in Q2 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 5.92 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 7.74 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 40.00 Mn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 3.92 Bn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 1.53 Bn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 1.88 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 4.20 Bn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 9.32 Bn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 1.17 Bn
10 Greenwich LifeSciences 231.59 Mn 231.59 Mn - 4.56 Mn
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 4.56 Mn
Dec 31, 2025 5.15 Mn
Jun 30, 2025 2.21 Mn
Mar 31, 2025 2.24 Mn
Dec 31, 2024 2.88 Mn